BioMarin Pharmaceutical Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies.
Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the stocks that could 10x by 2030. On May 22, H.C. Wainwright reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with a $50 price target. The cautious outlook comes on the heels of BioMarin Pharmaceutical delivering positive Phase 3 Pivotal study results for VOXZOGO. The study met […]
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the stocks that could 10x by 2030. On May 22, H.C. Wainwright reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with a $50 price target. The cautious outlook comes on the heels of BioMarin Pharmaceutical delivering positive Phase 3 Pivotal study results for VOXZOGO. The study met […]
Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.
Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 7.3% in the afternoon session after the company announced positive results from a late-stage study for its top-selling medicine, Voxzogo, which could expand its use.
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 7.3% in the afternoon session after the company announced positive results from a late-stage study for its top-selling medicine, Voxzogo, which could expand its use.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
BioMarin stock climbed after Phase 3 VOXZOGO data showed significant growth improvements in children with hypochondroplasia.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best low priced stocks to buy for the next 3 years. On May 18, BioMarin’s Phase 3 ENERGY 3 trial of BMN 401 for children with ENPP1 deficiency met only one of its two co-primary endpoints. Treatment led to statistically significant increases in plasma inorganic pyrophosphate/PPi concentration […]
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best low priced stocks to buy for the next 3 years. On May 18, BioMarin’s Phase 3 ENERGY 3 trial of BMN 401 for children with ENPP1 deficiency met only one of its two co-primary endpoints. Treatment led to statistically significant increases in plasma inorganic pyrophosphate/PPi concentration […]
Earlier this week, BioMarin Pharmaceutical reported mixed pivotal Phase 3 ENERGY 3 results for BMN 401 in children with ENPP1 deficiency, showing a statistically significant rise in plasma PPi but no improvement in key skeletal clinical endpoints or radiographic measures of rickets. The outcome highlights the challenge of translating promising biomarker changes into measurable clinical benefit, a core consideration for rare disease drug development and regulatory assessment. Next, we’ll...
Earlier this week, BioMarin Pharmaceutical reported mixed pivotal Phase 3 ENERGY 3 results for BMN 401 in children with ENPP1 deficiency, showing a statistically significant rise in plasma PPi but no improvement in key skeletal clinical endpoints or radiographic measures of rickets. The outcome highlights the challenge of translating promising biomarker changes into measurable clinical benefit, a core consideration for rare disease drug development and regulatory assessment. Next, we’ll...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 CANOPY-HCH-3 study evaluating treatment with VOXZOGO® (vosoritide) in children with hypochondroplasia met its primary endpoint, demonstrating a statistically significant increase in the change from baseline at week 52 in annualized growth velocity (AGV) compared to placebo (LS mean difference +2.33 cm/yr, p<0.0001). Children who received VOXZOGO also showed a statistically significant increase in standing height (p<0.00
BioMarin shares fall after BMN 401 meets a biomarker goal but misses a key radiographic endpoint in a late-stage ENPP1 deficiency study.
BioMarin shares fall after BMN 401 meets a biomarker goal but misses a key radiographic endpoint in a late-stage ENPP1 deficiency study.
B of A Securities analyst Jason Zemansky maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $85 to $80.
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 7.30M | $412.10M | 0.01% | Trimmed-3.0% | 2026-03-31 |
| Viking | long/short | 7.06M | $398.94M | 1.12% | Added+17.0% | 2026-03-31 |
| FidelityFMR | fundamental | 3.57M | $201.50M | 0.01% | Added+94.2% | 2026-03-31 |
| CapResearch | fundamental | 3.49M | $197.23M | 0.03% | Added+37.1% | 2026-03-31 |
| Citadel | multi-strat | 1.20M | $67.74M | 0.09% | Added+173.3% | 2026-03-31 |
| RenTech | quant | 1.02M | $57.89M | 0.09% | Trimmed-22.6% | 2026-03-31 |
| Wellington | fundamental | 716.5K | $40.48M | 0.01% | Trimmed-8.7% | 2026-03-31 |
| DEShaw | quant | 282.5K | $15.96M | 0.01% | Trimmed-71.9% | 2026-03-31 |
| Bridgewater | macro | 206.9K | $11.69M | 0.05% | Trimmed-10.0% | 2026-03-31 |
| TwoSigma | quant | 44.5K | $2.51M | 0.00% | Trimmed-36.3% | 2026-03-31 |
| TRowePrice | fundamental | 176.3K | $9.96K | 0.00% | Added+11.9% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-03upcoming | 0.96 | — | — |
| 2026-05-04 | 0.91 | 0.76 | -16.86% |
| 2026-02-23 | 0.56 | 0.46 | -17.94% |
| 2025-10-27 | 0.34 | 0.12 | -64.34% |
| 2025-08-04 | 1.03 | 1.44 | +39.40% |
| 2025-05-01 | 0.95 | 1.13 | +18.58% |
| 2025-02-19 | 0.74 | 0.92 | +24.57% |
| 2024-10-29 | 0.79 | 0.91 | +14.73% |
| 2024-08-05 | 0.60 | 0.96 | +60.99% |
| 2024-04-24 | 0.60 | 0.71 | +18.33% |
| 2024-02-22 | 0.45 | 0.49 | +9.50% |
| 2023-11-01 | 0.48 | 0.46 | -4.66% |
| 2023-07-31 | 0.47 | 0.54 | +14.29% |
| 2023-04-26 | 0.40 | 0.60 | +48.49% |
| 2023-02-27 | 0.39 | 0.36 | -6.30% |
| 2022-10-26 | 0.43 | 0.45 | +4.85% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BMRN | +5.97% | -2.12% | -3.60% | -1.34% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +3.01% | +2.52% | -0.16% | -14.03% |